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Background: Despite availability of efficient treatment regimens for early stage colorectal cancer, treatment
regimens for late stage colorectal cancer are generally not effective and thus need improvement. Oncolytic
virotherapy using replication-competent vaccinia virus (VACV) strains is a promising new strategy for therapy of a
variety of human cancers.
Methods: Oncolytic efficacy of replication-competent vaccinia virus GLV-1h68 was analyzed in both, cell cultures
and subcutaneous xenograft tumor models.
Results: In this study we demonstrated for the first time that the replication-competent recombinant VACV GLV-1h68
efficiently infected, replicated in, and subsequently lysed various human colorectal cancer lines (Colo 205, HCT-15,
HCT-116, HT-29, and SW-620) derived from patients at all four stages of disease. Additionally, in tumor xenograft
models in athymic nude mice, a single injection of intravenously administered GLV-1h68 significantly inhibited tumor
growth of two different human colorectal cell line tumors (Duke’s type A-stage HCT-116 and Duke’s type C-stage
SW-620), significantly improving survival compared to untreated mice. Expression of the viral marker gene ruc-gfp
allowed for real-time analysis of the virus infection in cell cultures and in mice. GLV-1h68 treatment was well-tolerated
in all animals and viral replication was confined to the tumor. GLV-1h68 treatment elicited a significant up-regulation of
murine immune-related antigens like IFN-γ, IP-10, MCP-1, MCP-3, MCP-5, RANTES and TNF-γ and a greater infiltration of
macrophages and NK cells in tumors as compared to untreated controls.
Conclusion: The anti-tumor activity observed against colorectal cancer cells in these studies was a result of direct viral
oncolysis by GLV-1h68 and inflammation-mediated innate immune responses. The therapeutic effects occurred in
tumors regardless of the stage of disease from which the cells were derived. Thus, the recombinant vaccinia virus
GLV-1h68 has the potential to treat colorectal cancers independently of the stage of progression.
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According to the American Cancer Society, cancer is the
second leading cause of death, with an estimated total of
577,190 deaths worldwide in 2012. Colorectal cancer is
the third-most diagnosed cancer and the fourth leading
cause of cancer death in both sexes. In 2012 in the
United States alone, there were estimated to be 103,170* Correspondence: aaszalay@genelux.com
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reproduction in any medium, provided the orcolorectal cancer-related deaths [1]. While standard
treatments of colorectal cancer can be up to 90% effective
for early stage disease, the 40-60% of patients with
recurring or late stage disease have few effective
treatment options.
Colorectal cancer begins as a benign adenomatous
polyp and eventually develops into a malignant and, if
untreated, metastatic cancer over the course of several
years. The most frequent mutations associated with
colorectal cancer are in genes of the Wnt signaling
pathway, the p53 and the TGF-β genes. Colon cancerstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatable and can oftentimes be cured with surgical
resection being the standard therapy [2]. Adenocarcin-
omas account for more than 95% of reported cases,
making it the most common colorectal cancer cell type.
Surgical excision provides cure rates of 90% in stage I and
75% in stage II, and postsurgical combination therapy with
5-Fluorouracil-based chemotherapeutic agents increases
the survival rate in stage III disease from 40% to 60% [3].
However, cases of surgical excision and chemotherapy still
show recurrence rates between 40-60% in the first three
years, with similarly high recurrence rates at later stages of
the disease, likely caused by chemoresistant cancer-
initiating cells [4,5]. Metastatic stage IV disease is incurable
and treatment becomes palliative. Newer and more
efficient treatment regimens are needed to reduce the still
considerably high treatment failure rates, especially in re-
curring cases or the late stages of colorectal cancer disease.
Among new therapeutic strategies, oncolytic virotherapy
has been explored recently for its target specificity and
relative safety in patients. Oncolytic viruses can efficiently
infect and kill tumor cells. These effects have been
observed for a number of viruses, including adenovirus,
West Nile virus, herpes simplex virus, measles virus,
Newcastle disease virus, and vaccinia virus [6,7]. While
studies suggest that some of these viruses may have
potential for oncolytic virotherapy of colorectal cancer
[8-10], none yet have been approved for treatment.
One of the best studied oncolytic viruses is vaccinia
virus. The antitumor effects of vaccinia virus are mediated
directly by viral infection, replication and lysis of cancer
cells and indirectly by inducing antivascular effects [11] as
well as stimulation of the host immune response [12].
Moreover, a significant advantage of vaccinia virus is its
long history of safe administration in humans as a
smallpox vaccine.
We reported previously the tumor selectivity and
anti-tumoral efficacy of the replication-competent recom-
binant vaccinia virus GLV-1h68 in different canine [13,14]
as well as human tumor xenograft models like breast can-
cer [15], anaplastic thyroid carcinoma [16,17], malignant
pleural mesothelioma [18], pancreatic tumor [19], prostate
carcinoma [20], squamous cell carcinoma [21], sarcomas
[22], and hepatocellular carcinoma [23]. In addition, we
showed functionality of second-generation recombinant
vaccinia viruses armed with the human norepinephrine
transporter [24] and the human sodium iodide symporter
gene [25] for PET imaging, or single-chain antibody
GLAF-1 targeting VEGF and tumor vascularization
in vivo [26]. We also demonstrated preferential replication
in glioblastoma cells and higher efficacy in treating gli-
omas in combination with radiation therapy [27]. Re-
cently, the first clinical Phase I trial of GLV-1 h68 was
completed [28] and three additional Phase I trials arecurrently ongoing (http://www.clinicaltrials.gov, 2012,
keyword: Genelux).
Here, we report for the first time the efficacy of
oncolytic vaccinia virus GLV-1h68 to infect, replicate in
and lyse various colorectal cancer cells in culture and in
tumor xenograft models, and we evaluate these effects
on cells derived from patients at different stages of




African green monkey fibroblasts (CV-1) and human colo-
rectal adenocarcinoma cells [HT-29 (Duke’s type B)] were
obtained from ATCC (ATCC-No. CCL-70 & HTB-38).
Human colon adenocarcinoma cells [Colo 205 (Duke’s type
D), HCT-15 & SW-620 (Duke’s type C)] and human colon
carcinoma cells [HCT-116 (Duke’s type A)] were obtained
from NIH as part of the NCI-60 collection. CV-1 cells were
cultured in DMEM (Cellgro) supplemented with 1×
antibiotic-antimycotic solution [100 U/mL penicillin G,
250 ng/mL amphotericin B, and 100 U/mL streptomycin)
(Cellgro) and 10% fetal bovine serum (FBS)(Cellgro)].
HCT-15, HCT-116, HT-29 and SW-620 cells were
cultured in RPMI 1640 (Cellgro) supplemented with 1×
antibiotic-antimycotic solution (100 U/mL penicillin G,
250 ng/mL amphotericin B, and 100 U/mL streptomycin)
and 10% FBS. Colo 205 cells were cultured in RPMI 1640
supplemented with 1× antibiotic-antimycotic solution
[100 U/mL penicillin G, 250 ng/mL amphotericin B, and
100 U/mL streptomycin), 1.5 g/L sodium bicarbonate
(Cellgro), 4.5 g/L glucose (Cellgro), 10 mM HEPES
(Cellgro), 1.0 mM sodium pyruvate (Cellgro) and 10%
FBS]. Cells were cultured at 37°C under 5% CO2.
Virus
The recombinant vaccinia virus GLV-1h68 used in this
study is a genetically stable, attenuated virus with
oncolytic activity and was derived and purified from
vaccinia virus strain LIVP as described earlier [15].
Briefly, three expression cassettes encoding for Renilla
luciferase Aequoria GFP fusion protein, β-galactosidase
and β-glucoronidase were inserted into the F14.5 L, J2R
and A56R loci, respectively, of the viral genome of the
LIVP strain.
Viral proliferation assay
Standard plaque assays were performed to quantify viral
replication following infection of different colorectal
cancer lines with GLV-1h68. Colorectal cancer (CRC)
cells were infected with GLV-1h68 at a multiplicity of in-
fection (MOI) of 0.01, 0.1 or 10 for 1 h at 37°C and 5%
CO2. Afterwards, the infection medium (RPMI 1640
supplemented with 2% FBS) was removed and cells were
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plemented with 10% FBS). Cells were then harvested
mechanically in triplicates after 6, 24, 48, 72 and 96 hours
post infection (hpi). Following three freeze-thaw cycles,
serial dilutions of the samples were titrated in triplicates
on confluent layers of CV-1 cells in 24-well plates. After
incubation for 48 h at 37°C and 5% CO2, plaques were
stained with cystal violet solution (crystal violet (Sigma) in
5% (w/v) ethanol (Sigma) and 30% (w/v) formaldehyde
(Fisher)).
Infection of cell cultures
Colorectal cancer cells and CV-1 cells were seeded into
24-well plates to achieve 95% confluence the next day.
After 24 h in culture, cells were infected with GLV-1h68
at MOIs of 1.0 and 0.1 in infection medium. Cells were
incubated for 1 h at 37°C, after which the infection
medium was removed, and cells were cultured in fresh
growth medium.
Cell viability assay
The amount of viable cells after infection with GLV-1h68
was measured using 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromid (MTT) (Sigma). Twenty-four,
48 and 72 hpi, the medium was replaced with 0.5 mL
sterile MTT solution at a concentration of 2.5 mg/mL
MTT dissolved in RPMI 1640 without phenol red and
incubated for 2 hours at 37°C in a 5% CO2 atmosphere.
After removal of the MTT solution, the color reaction was
stopped by adding 1 N HCl diluted in isopropanol. The
optical density was then measured at a wavelength of
570 nm using a SpectraMax microplate reader (Molecular
Devices). Uninfected cells were used as a reference and
considered as 100% viable.
Cell proliferation assay
The proliferation rate of viable HCT-15 and HCT-116 was
measured using 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide (XTT) (Roche). HCT-15
and HCT-116 cells were seeded at a concentration of
1×103 cells/well in 96-well plates and proliferation was
measured after 24, 48, 72, 96 and 120 hours. Substrate was
added according to manufacturer’s instructions and cells
were incubated for four hours at 37°C. Optical density
was measured at wavelengths of 450/700 nm using a
SpectraMax microplate reader (Molecular Devices).
Fluorescence microscopy
An inverted microscope (Olympus IX71) was used to
capture images with a MicroFireW (Olympus) digital
CCD camera. Brightfield and fluorescence images were
taken 24, 48 and 72 hpi to follow the course of infection
and pseudocolored using the open source GIMP2.6
software.Flow cytometry analysis
Infected cells were analyzed 24, 48 and 72 hpi. Cells were
harvested by Trypsin-EDTA (Cellgro) and resuspended in
PBS (Cellgro). For discrimination between viable and dead
cells, CRC cells were stained using 5 μL propidium iodide
solution (1 mg/mL; Molecular Probes) per 0.5 mL cell
suspension for 20 min at 37°C. A total of 7.5×104 cells per
sample were then measured for GFP and propidium
iodide signals using a Cell Lab Quanta™ SC flow
cytometer (Beckman Coulter) and analyzed using Quanta
Analysis software (Beckman Coulter).
Subcutaneous HCT-116 and SW-620 xenografts
Mice were cared for in accordance with approved protocols
by the Institutional Animal Care and Use Committee of
Explora Biolabs (San Diego Science Center, protocol
number EB11-025). Five- to six-week old male Hsd:
athymic Nude-Foxn1nu mice (Harlan) were implanted
subcutaneously (s.c.) with 5×106 HCT-116 cells or SW-620
cells (in 100 μL PBS) into the right hind leg. Treatment
started when tumors reached a volume of 200–300 mm3.
GLV-1h68 was administered systemically by intravenous
(i.v.) injection into the lateral tail vein of 5×106
plaque-forming units (pfu) in 100 μL PBS at day 0. Control
animals were injected i.v. with 100 μL PBS only. Tumor
growth was measured using a digital caliper and tumor
volume was calculated as 0.5 × (height-5) × width × length
(mm3). Average tumor volume (ATV) was used to moni-
tor therapeutic efficacy. Net body weight was calculated
from the measured body weight (body weight – tumor
volume/1000 mm3) to exclude tumor mass. Mice were
sacrificed when the body weight dropped by one third of
their original body weight or the tumor volume exceeded
4000 mm3. The experiment was terminated 42 days post
injection (dpi).
Vaccinia viral titers in tumor xenografts and body organs
Tumors and body organs (spleen, kidney, liver, testes,
lungs) of five virus-treated animals were excised at 7 and
14 days post injection and placed in two volumes (w/v) of
homogenization buffer (50 mM Tris–HCl (pH 7.4) (Fisher),
2 mM EDTA (pH 7.4) (Sigma)) supplemented with
Complete Protease Inhibitor Cocktail (Roche Diagnostics).
Tumors were then homogenized using a MagNA Lyser
(Roche Diagnostics) at a speed of 6,000 for 30 s (three
times). Following three subsequent freeze-thaw cycles
(liquid N2/37°C water bath), supernatants were collected by
centrifugation (6,000 rpm, 5 min, 4°C). Viral titers were
measured by standard plaque assays on CV-1 cells.
Preparation of tumor lysates for mouse immune-related
protein profiling
Tumor lysates were prepared, at 21 days post injection,
from three mice of each treatment group. Tumors were
Figure 1 Analysis of viral titers after infection of five different
CRC lines with GLV-1h68 in culture. Cells were infected at an MOI
of 0.1 and samples were collected at various times after infection.
Titers were averaged from triplicates and normalized to pfu/1x106
cells. Averages plus standard deviations are plotted.
Ehrig et al. Journal of Translational Medicine 2013, 11:79 Page 4 of 15
http://www.translational-medicine.com/content/11/1/79excised surgically, weighed and resuspended in 9 volumes
(w/v) lysis buffer [50 mM Tris–HCl (pH 7.4), 2 mM
EDTA (pH 7.4), 2 mM PMSF and Complete Mini protease
inhibitors (Roche)] and homogenized using a MagNA
Lyser (Roche Diagnostics) at a speed of 6,000 for 30 s
(three times). Supernatants were collected by centrifuga-
tion (6,000 rpm, 5 min, 4°C) and analyzed for mouse
immune-related protein antigen profiling by Multi-
Analyte Profiles (mouse MAPs; Rules Based Medicine)
using antibody linked beads. Results were normalized
based by the total protein concentration of each sample
and presented as mean antigen amount [n=3] per mg total
protein. Total protein concentrations were determined
using the DC Protein Assay Kit (BioRad) according to the
manufacturer’s instructions.
Preparation of single cell suspensions and fluorescence-
activated cell sorting
Single cell suspensions of tumors were prepared at 21 days
post virus injection from four untreated and five treated
animals. Tumors were surgically excised, weighed, and
minced into small (1–2 mm3) pieces with a scalpel, and
immersed in 10 mL of digestion mixture [5% FBS in RPMI
1640, 0.5 mg/mL collagenase D (Roche), 0.2 mg/mL
hyaluronidase, type V (Sigma), and 0.02 mg/mL DNase I
(Sigma)] per 0.25 g of tumor tissue. The suspension
was incubated with agitation at 37°C for 45 min. The
suspension was then filtered sequentially through 70- and
40-μm cell strainers (BD Falcon) and washed with 5% FBS
in RPMI 1640. Red blood cells (RBCs) were lysed by brief
incubation with an ammonium chloride-based lysis buffer
(BD Biosciences) and cell debris/dead cells were removed
by centrifugation. The single cell suspensions obtained
were labeled with F4/80 (BD Biosciences) / CXCR4
(BD Biosciences) or CD19 (BD Biosciences) / DX5
(BD Biosciences) antibodies for macrophage or NK cell
identification, respectively, and analyzed on a two-laser
FACSCanto (BD Biosciences) fluorescence cell sorter.
CountBright™ counting beads (Invitrogen) were used
according to the manufacturer’s instructions to quantify
total cell numbers in the samples.
Histological analysis of tumors
Tumors were surgically excised and snap-frozen in liquid
N2, followed by fixation in 4% paraformaldehyde (EMS)/
PBS at pH 7.4 for 16 h at 4°C. Tissues were washed in PBS
and embedded in 5% low melt agarose (Fisher). Tissues
were cut using a VT1200S (Leica) vibratom into 100 μm
sections and subsequently permeabilized in 0.2% Triton-X
100 (Fisher), 5% FBS in PBS. GFP expression was used as
an indicator for viral distribution within the tumor tissue.
Phalloidin-TRITC (Sigma) was used to label actin. The
fluorescent-labeled preparations were examined using a
Leica MZ 16 FA Stereo-Fluorescence microscope equippedwith a FireWire DFC/IC monochrome CCD camera
(Leica). Digital images were processed with GIMP2
(Freeware) and merged to yield pseudocolored images.
Expression of the virus-encoded marker gene GFP
GFP expression within tumors was detected under blue
light using a stereo fluorescence macroimaging system
(Lightools Research). GFP expression was scored using a
four point system: 0) no GFP signal, 1) one spot, 2) two
or three local spots, 3) diffuse signal from half the
tumor, 4) strong signal from the whole tumor.
Statistical analysis
Statistical analyses were performed with SPSS, version 11
(SPSS, Inc.). Comparisons of treatment groups were made
by ANOVA, and the differences between the groups were
analyzed with a least significant difference (LSD) test
when the ANOVA showed an overall significance. Values
of P less than 0.05 were considered significant.
Results
Replication and cytotoxicity of GLV-1h68 in human
colorectal cancer cell lines
The replication of recombinant vaccinia virus GLV-1h68
was analyzed in different human colorectal cancer cells in
culture (Colo 205, HCT-15, HCT-116, HT-29 and
SW-620). These cells represent the common colorectal
tumor cell types, human colon adenocarcinoma (HCT-15,
HCT-116, HT-29 and SW-620) and human colon
carcinoma (Colo 205), and were obtained from patients
at all four stages of disease (Duke’s type A through D).
Duke’s classification is a widely applied classification
system for colorectal cancer, the predecessor of the
current TNM staging system. HCT-116 (Duke’s type A),
HT-29 (Duke’s type B) and HCT-15 cells (Duke’s type C)
are derived from primary tumors whereas SW-620 cells
Ehrig et al. Journal of Translational Medicine 2013, 11:79 Page 5 of 15
http://www.translational-medicine.com/content/11/1/79(Duke’s type C) were derived from the lymph nodes and
Colo 205 cells (Duke’s type D) from the ascites. While
GLV-1h68 replicated in all five cell lines (Figure 1) the
replication efficiency between the infected cell lines varied.
Higher titers after 24 hpi were observed for HT-29
(2.9×106 ± 8.5×105 pfu/106 cells), HCT-116 (1.7×106 ±
2.6×105 pfu/106 cells) and Colo205 cells (1.4×106 ±
3.8×105 pfu/106 cells) and somewhat lower titers were
observed for HCT-15 (5.5×105 ± 1.1×104 pfu/106 cells)
and SW-620 cells (9.9×104 ± 1.6×104 pfu/106 cells). Titers
in the tested cell lines reached a maximum after 48 to
72 hours post infection (1.91×107 pfu/106 cells in
infected HT-29 cells and 6.58×105 pfu/106 cells in SW-
620), except for HCT-116 and Colo 205, which peaked
24 hours post infection.
Cell viability assays were performed to assess the
cytotoxicity of GLV-1h68 infection in culture at MOIs ofFigure 2 Cell viability of human colorectal cancer lines after GLV-1h6
(B) and assayed for viable cells using the MTT assay over a time course of 7
averaged. Averages were normalized against the uninfected controls at eac0.1 and 1.0 (Figure 2). While differences were observed
between the cell lines and at different MOIs, all five hu-
man colorectal cancer cell lines displayed significant
cytotoxicity after infection. GLV-1h68 displayed greatest
cytotoxicity in HCT-116 cells and was least cytotoxic in
HCT-15. At 48 hours post infection, only 19.2 ± 0.7%
(MOI 0.1) and 1.8 ± 0.8% (MOI 1.0) of HCT-116
remained viable.
We investigated whether the susceptibility to cytotoxicity
by GLV-1h68 observed in the CRC cell lines might be due
to factors affecting cell infectivity or viral spreading.
Plaque formation in HCT-15 (low susceptibility) and
HCT-116 (high susceptibility) was compared to CV-1 cells
(our standard laboratory cell line for propagation of
vaccinia virus). No significant difference in plaque number
was observed after infection for 24 hours with the same
number of pfu (Figure 3A). Evaluation of the growth in8 infection. Cells were infected in culture at MOIs of 0.1 (A) and 1.0
2 hours. Viability was measured in two sets of triplicates and
h time-point which were considered to be 100% viable.
Figure 3 Analysis of cell susceptibility to GLV-1h68 cytotoxicity in HCT-15 and HCT-116 CRC cells. A) Plaque forming ability in CV-1 cells
(standard), HCT-15 (low cytotoxicity), and HCT-116 (high cytotoxicity). All cell lines were tested in triplicates with a dose of 1x108 pfu of GLV-1h68
for 24 hours at 37°C. Cells were then harvested and plaque forming ability was determined by standard plaque assay. Average titers were
determined from triplicates and expressed as pfu/mL. Averages plus standard deviations were plotted. B) Cell proliferation of HCT-15 and HCT-
116. Cells were seeded at a concentration of 1x103 cells/well and cell proliferation was followed for 24, 48, 72, 96 and 120 hours. Cell lines were
tested in quadruplicates and averages plus standard deviations are plotted. C) Replication of GLV-1h68 at low and high MOIs. Cells were infected
at an MOI of 0.01 (low) or 10 (high) and samples were collected at 6, 24, and 48 hours after infection. Average titers were determined in from
triplicate and normalized to pfu/1x106 cells. Averages plus standard deviations are plotted.
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HCT-116 cells proliferated significantly (P≤0.05) faster
than HCT-15 cells during the first 72 hours (Figure 3B).
After 24 and 48 hours of infection at an MOI of 0.01,
mimicking the virus:tumor cell ratio in vivo, GLV-1h68
replicated significantly faster (P≤0.005) in HCT-116
cells compared to HCT-15 cells, although there was no
significant difference at an MOI of 10 (Figure 3C).
To investigate whether antiviral type I IFN-α/β signaling
in infected host cells contributed to virus susceptibility,
HCT-15 and HCT-116 were infected with low dose
(MOI 0.01) and high dose (MOI 5.0) of GLV-1h68. The
supernatant of the infected cells was then analyzed by
ELISA at different time points after infection (30, 60,
120, and 360 min, 24 h) for IFN-α and IFN-β secretion.
Neither HCT-15 nor HCT-116 cells yielded measurable
amounts of secreted IFN-α or IFN-β after infection with
GLV-1h68 (data not shown). Therefore, the greater
observed cytotoxicity of the CRC cell lines after GLV-1h68
infection was associated with greater efficiency of
GLV-1h68 replication and greater proliferation rate of thecells, not with differences in infectivity or with the produc-
tion of type I IFN.
Analysis of virus-mediated marker protein expression
The correlation of viral replication and cell death in
GLV-1h68-infected CRCs was evaluated microscopically
by identifying cells expressing the GLV-1h68-mediated
Ruc-GFP transgene product in HCT-116 cells at two
different MOIs. Cell morphology changes were followed
in bright field images over the course of 72 h (Figure 4,
upper row). Green fluorescent protein expression, as a
marker for viral infection and replication, was visualized
by fluorescence microscopy (Figure 3, second row).
Propidium iodide staining was used to identify dead cells
(Figure 3, third row). Infection, replication and gene
expression of Ruc-GFP from GLV-1h68 occurred
efficiently (Figure 4 & Additional file 1) in a MOI- and
time-dependent manner after infection of all tested cell
lines (data not shown). Cell death and CPE (cytopathic
effects) increased following Ruc-GFP expression. The
overlay image in Figure 4, third row, demonstrates the
Figure 4 Fluorescence microscopy of virus-mediated Ruc-GFP expression in HCT-116. HCT-116 cells were infected at an MOI of 1.0 and
monitored for 72 hours. (BF) shows bright field microscopic images of the morphology of virus-infected cells. (GFP) expression in infected cells
was visualized by direct fluorescence microscopy; propidium iodide (PI) was used as a marker for dead cells. Colocalization of (GFP) and (PI) signal
is shown in the (merged) images. All pictures were taken at 40x magnification.
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propidium iodide staining in the same cells. Thus,
GLV-1h68 infection and replication proceeded to cell
death in a majority of cells imaged.
This coincidence was also confirmed and quantified by
flow cytometry analysis of GLV-1h68-infected (GFPpos)
and dead cells (propidium iodide staining). After infection
of HCT-116 cells with GLV-1h68 at an MOI of 0.1, the
GFPpos cell fraction increased from 57.1 ± 5.9% at 24 hours
to 62.3 ± 3.5% at 48 hours and 75.4 ± 3.1% at 72 hours,
consistent with the increased infection and replication of
the virus. The fraction of these cells (GFPpos) that were
also propidium iodide positive progressively increased
from 6.4 ± 1.9% at 24 hours to 37.9 ± 1.8% at 48 hours
and 72.2 ± 2.7% at 72 hours. At the last time point, the
majority of cells were either virus-infected or dead (75.4% ±
3.1%). At an MOI of 1.0, the observed results were similar,
except accelerated. In agreement with the in vitro cell
culture results, GLV-1h68 showed highest efficacy of repli-
cation and cytotoxicity in HCT-116 and Colo 205, followed
by HT-29 and SW-620 and was least effective in HCT-15
cells. Thus, GLV-1h68 efficiently infected, replicated inand ultimately killed human colorectal cancer cells in
culture, as confirmed by FACS analysis (Figure 5 and
Additional file 2).A single dose of GLV-1h68 causes tumor growth
inhibition in HCT-116 and SW-620 xenografts
We next examined the efficacy of GLV-1h68 to target and
affect the growth of HCT-116 (Duke’s type A) xenograft
tumors in mice. HCT-116-tumor bearing mice were
injected subcutaneously either with 5×106 of GLV-
1h68 (n=10) or PBS only (n=5) when the tumor vol-
ume reached an average of 250 mm3. Tumor volume
was determined by physical measurement of the palpable
tumors. Starting at 14 days post injection, animals receiv-
ing a single dose of GLV-1h68 had significantly (P≤0.05)
inhibited tumor growth. This tumor growth inhibition be-
came highly statistically significant (P≤0.0005) 21 days
after virus injection and persisted from Day 28 through
the end of the study at Day 42 (Figure 6). Overall, after
injection of GLV-1h68, the tumors of virus-treated ani-
mals grew to three times their starting volume whereas
Figure 5 Flow cytometry analysis of GLV-1h68-infected HCT-
116 cells. Cells were infected at MOIs of 0.1 or 1.0. Data represents
the average distribution of uninfected/infected [GFP neg/pos] and
viable/dead [PI neg/pos] cells over the course of 72 hours
post infection.
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starting volume.
The general health of virus-treated animals was not
adversely affected as indicated by only a slight decrease
in net body weightof the tumor-bearing animals. Seventy
percent (70%) of GLV-1h68-treated animals survived the
duration of the study to Day 42, whereas all untreated
animals had to be sacrificed due to high tumor burden by
Day 35 (Additional file 3). GLV-1h68-treatment was
evaluated in a second tumor xenograft model in mice to
examine whether cell line- or stage-specific differences oc-
curred using the slow responding cell line SW-620 (Duke’sFigure 6 Effects of a single administration of GLV-1h68 on
tumor growth of HCT-116 tumor-bearing mice. HCT-116 cells
were implanted subcutaneously in the right hind leg of athymic
nude mice and GLV-1h68 treatment was evaluated versus PBS
treatment. Average tumor volume (ATV) for GLV-1h68-treated (n=10)
and for PBS treated control mice (n=5) is plotted over time after
treatment and one-way analysis of variance (ANOVA) was used to
compare the data. P ≤ 0.05 was considered statistically significant;
* = P ≤ 0.05, *** P ≤ 0.0005.type C). SW-620-tumor bearing mice were injected either
with 5×106 pfu GLV-1h68 (n=10) or PBS. Again, inhib-
ition of tumor growth after a single injection of GLV-
1h68 was observed, becoming statistically significant
(P≤0.05) after 21 days after virus injection. Untreated
tumors grew approximately two-fold bigger than virus-
treated tumors after 35 days of treatment (Additional
file 4). The results indicate that in this model, GLV-1h68
treatment effectively inhibited the growth of both CRC
tumors, from HCT-116 (Duke’s type A, fast proliferating,
highly susceptible to GLV-1 h68 replication and cyto-
toxicity in culture) and SW-620 (Duke’s type C, slow
proliferating, less susceptible to GLV-1h68 replication
and cytotoxicity in culture than HCT-116).
Replication of GLV-1h68 after injection is confined to the
primary tumor site
To analyze the specific tumor-targeting ability of
GLV-1h68, animals bearing HCT-116 tumors (n=5)
were sacrificed 3 and 14 days after intravenous injection
of the virus. Various body organs (testes, spleen, liver,
kidney, lungs) and the primary tumor were excised,
prepared and analyzed by standard plaque assay to evaluate
viral spreading in the animals (Table 1). At three days after
injection, 2.94×105 ± 5.54×105 viral pfu were detected in
the primary tumors, whereas negligible or no infective
virus was detected in the body organs. Even well-
vascularized tissues like the liver or lungs showed no or
very low numbers of plaque forming vaccinia virus
particles, indicating rapid and efficient clearance from
the blood stream. Between three and 14 days post injection,
a two-log increase in viral titers in the primary tumor tissue
was detected whereas no virus (testes, spleen, kidneys) or
negligible amounts of virus (liver, lungs) were found in
normal tissues.
GLV-1h68 infection and replication in vivo was also
assessed by live, whole body fluorescence imaging andTable 1 Viral titers in mouse tissues or tumors
Viral Titers (mean ± standard deviation)[pfu/g]
Tissue 3 dpi # 14 dpi #
tumor 2.94 × 105 ± 5.54 × 105 5/5 4.21 × 107 ± 2.48 × 107 5/5
lungs 4.21 ± 6.11 1/5 2.62 ± 3.59 2/5
liver n.d. 0/5 3.88 ± 8.68 1/5
spleen n.d. 0/5 n.d. 0/5
kidney n.d. 0/5 n.d. 0/5
testes n.d. 0/5 n.d. 0/5
The viral titers in mouse tissues or tumors are shown. HCT-116-bearing mice
[n=5] were sacrificed 3 days or 14 days [dpi] after i.v. injection of 5x106 pfu
GLV-1h68. Tissues and tumors were surgically excised, homogenized and viral
titers were determined by standard plaque assay. Titers are displayed as
means of all animals sacrificed per time point and in # column of the table
indicates the number of positively tested animals out of all the tested animals
in the group. n.d. = not detected.
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in tumors and surrounding tissues, which was possible
due to the negligible absorption of the GFP fluorescence
signal by the tissues (Figure 6). GFP fluorescence in the
tumor was clearly visible as early as 7 days post injec-
tion, increased until 21 days post injection, and
remained relatively stable thereafter to Day 42 (Figure 7).
The extent and intensity of GFP fluorescence in the
tumor as a marker for GLV-1h68 infection and replica-
tion was also confirmed by histological examination ofFigure 7 Virus-mediated Ruc-GFP expression at the local tumor site o
GLV-1h68-treated mice during the course of the experiment. GFP intensity
signal, 1) one spot, 2) two or three local spots, 3) diffuse signal from half th
standard errors for groups of five mice at each time point are presented. B
shown for one representative mouse.tumor sections at 21 and 42 days post injection. The
merged images of Phalloidin-TRITC staining of actin
and GFP fluorescence demonstrated that GLV-1h68 spe-
cifically infected cells within the tumor (Figure 8).
Effects of a GLV-1h68 injection on the host immune system
To evaluate the role of the host immune system in virus
clearance and the involvement in tumor growth inhib-
ition, mice bearing HCT-116 tumors were either treated
by a single intravenous injection of GLV-1h68 or treatedf HCT-116-bearing mice. A) Analysis of GFP fluorescence intensity in
is determined by using a four level visual scoring system; 0) no GFP
e tumor, 4) strong signal from whole tumor. Average scores with
) Fluorescence imaging of GFP expression at the local tumor site is
Figure 8 Histochemical staining of HCT-116 tumor sections. Microscopic images of histological sections of representative HCT-116 tumors
from an untreated mous at 21 days post-injection [A] and GLV-1h68-treated mice [B] at 21 and 42 days post-injection [dpi] are shown. Images
were obtained under bright field (BF) or fluorescence microscopy (Phalloidin-TRITC, GFP). Digital images were processed with GIMP2 (Freeware)
and merged to yield pseudocolored images (merged). Whole tumor cross-sections (thickness = 100 μm) were labeled with Phalloidin-TRITC to
detect de novo synthesis of actin as an indicator for live cells. GFP fluorescence indicates GLV-1h68 replication in the tumor.
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jection, when the differences in tumor volume first be-
came statistically significant (P≤0.0005). Tumor tissue
lysates were prepared for immune-related antigen
profiling. The data from virus-treated and untreated
xenografts showed that treatment with GLV-1h68 was
associated with increased levels of many pro-inflammatory
cytokines and chemokines (GCP-2, KC/GRO alpha, IFN-γ,
IP-10, IL-3, IL-6, Lymphotactin, M-CSF1, MIP-1 beta,
MCP-1, MCP-3, MCP-5, RANTES) (Table 2). Only a few
markers were down-regulated upon virus treatment (FGF-
beta, MIP-1 alpha, MIP-1 gamma, SGOT).
Immune cell infiltration in tumors was evaluated by
preparing single cell suspensions from surgically excised
tumors of untreated and treated animals 21 days post
injection, and analysis by flow cytometry (Figure 9).
Representing infliltrating innate immune cells, macro-
phages were identified using the cell antigen-specific
markers F4/80 and CXCR4 and NK cells were identified
using CD19 and DX5. HCT-116 tumors treated with
GLV-1h68 had a significantly (P≤0.05) greater number of
F4/80low CXCR4pos macrophages and CD19pos DX5pos NK
cells than untreated tumors.
Discussion
Colorectal cancer (CRC) is among the most abundant
cancer types occurring in both sexes. Despite a generally
good prognosis after treatment of early stage disease
with standard therapy regimens, overall prognosis for
patients diagnosed with stage IV colorectal cancer re-
mains poor and recurrence rates after resection of
primary tumors are high. Moreover, aggressive surgeryand chemotherapy used to treat these cases are extremely
debilitating on the patient. Therefore, the development of
novel treatments for colorectal cancer that reduce recur-
rence rates and improve treatment efficacy especially of
late stage CRC is highly desirable.
In these studies, we demonstrate for the first time that
oncolytic vaccinia virus GLV-1h68 efficiently infected,
replicated in, and lysed a variety of human CRC lines in
culture. The observed oncolytic activity of GLV-1h68
occurred in both CRC cell types (colorectal adenocarcin-
oma and colorectal carcinoma) and appeared not to be
dependent on the stage of disease, as the cell lines studied
were derived from patients at all four Duke’s type clinical
stages (from Duke’s type A, primary tumor, to Duke’s
type D, metastatic disease). Viral replication, measured
either by plaque formation or by expression of the
virus-encoded Ruc-GFP, correlated with cell killing.
Flow cytometry analysis and fluorescence microscopy
confirmed that GFP expression was coincident with or
preceded cell death in the virus-treated cell population.
Our findings did show, however, that the different cell
lines varied in degree of viral replication and cytotoxicity,
and these differences were MOI-dependent. These results
agree with reports by Ascierto et al. that GFP marker gene
expression intensity upon infection with oncolytic vaccinia
virus is cell line-dependent [29]. Yet, none of the five
human colorectal cancer cell lines tested in culture
showed any evidence of resistance to either infection,
replication or subsequent lysis by GLV-1h68 in culture.
These results suggest that GLV-1h68 oncolytic virotherapy
could be generally applicable to the treatment of CRCs
regardless of the cell type of origin and independent of the
Table 2 Comparison of mouseMAPS in homogenates of untreated or GLV-1h68-treated HCT-116 tumors
Antigen Untreated GLV-1h68 P value Ratio
CD40 31.87 ± 10.5 fg/mg 193.41 ± 27.53 fg/mg ** 6.1
Eotaxin 1.24 ± 0.67 fg/mg 371.48 ± 122.26 fg/mg * 300.0
GCP-2 mouse 0.03 ± 0.009 pg/mg 0.50 ± 0.29 pg/mg * 19.3
KC/GRO 0.002 ± 0.001 pg/mg 0.073 ± 0.018 pg/mg ** 34.9
IFN gamma 1.61 ± 0.03 fg/mg 7.21 ± 0.35 fg/mg *** 4.5
IP-10 2.20 ± 0.71 fg/mg 145.28 ± 27.64 fg/mg ** 66.2
IL-1 alpha 14.18 ± 2.02 fg/mg 78.76 ± 7.82 fg/mg *** 5.6
IL-3 0.082 ±0.018 fg/mg 0.45 ± 0.18 fg/mg * 5.5
IL-6 1.63 ± 0.57 fg/mg 20.24 ± 12.76 fg/mg 12.5
IL-10 9.89 ± 1.68 fg/mg 52.48 ± 0.46 fg/mg *** 5.3
IL-11 6.03 ± 1.70 fg/mg 41.71 ± 9.32 fg/mg ** 6.9
IL-17A 5.20 ± 0.93 fg/mg 52.96 ± 6.40 fg/mg *** 10.2
IL-18 1.41 ± 0.08 pg/mg 8.03 ± 2.33 pg/mg * 5.7
Lymphotactin 14.25 ± 3.87 fg/mg 235.25 ± 36.29 fg/mg *** 16.5
M-CSF-1 318.57 ± 7.40 fg/mg 122.67 ± 35.91 fg/mg ** 38.5
MIP-1 beta 25.70 ± 8.90 fg/mg 1286.62 ± 206.46 fg/mg *** 50.1
MIP-2 1.20 ± 0.38 fg/mg 65.92 ± 30.24 fg/mg * 55.1
MIP-3 0.065 ± 0.01 fg/mg 0.36 ± 0.03 fg/mg *** 5.5
MMP-9 9.93 ± 7.02 pg/mg 91.31 ± 60.77 pg/mg 9.2
MCP-1 14.55 ± 4.65 fg/mg 3332.49 ± 93.80 fg/mg *** 229.1
MCP-3 18.20 ± 7.64 fg/mg 2023.74 ± 386.90 fg/mg *** 111.2
MCP-5 11.91 ± 6.71 fg/mg 676.99 ± 187.73 fg/mg ** 56.8
RANTES 0.0052 ± 0.003 fg/mg 0.54 ± 0.11 fg/mg ** 105.7
TIMP-1 mouse 1.30 ± 0.22 pg/mg 12.22 ± 4.53 pg/mg * 9.36
TNF alpha 5.38 ± 0.59 fg/mg 23.01 ± 2.51 fg/mg *** 4.27
FGF-b 107.94 ± 16.12 pg/mg 69.86 ± 15.26 pg/mg * 1.5
MIP-1 alpha 0.23 ± 0.008 pg/mg 0.13 ± 0.034 pg/mg * 1.7
MIP-1 gamma 0.94 ± 0.15 pg/mg 0.30 ± 0.03 pg/mg ** 3.1
SGOT 2.08 ± 0.72 pg/mg 1.08 ± 0.56 pg/mg 1.9
The table compares the levels of mouse immune-related protein antigen profiling in homogenates of untreated and GLV-1h68-treated HCT-116 tumors
normalized to total protein per sample 21 days after virus injection [n=3]. The ratio of antigen in GLV-1h68-treated and untreated animals and the level of
statistical significance are shown. * = P≤0.05, ** = P≤0.005, *** = P≤0.0005.
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different doses and/or regimens.
It is known that vaccinia virus depends on proliferating
cells for its replication [30]. Thus, fast replicating tumor
cells are better hosts for oncolytic vaccinia virus repli-
cation and consequently are more susceptible to the
cytotoxic effects and subsequent oncolytic effects of
GLV-1h68. Indeed, our results showed that the rate of
replication of GLV-1h68 in the five CRC cell lines
correlated with their rate of cell proliferation. Another
factor contributing to the observed differences in the
oncolytic effects of the different cell lines could be
GLV-1h68’s ability to evade the host cell defense
mechanisms (type-I IFN signaling, Toll-like receptor(TLR) signaling, interleukin signaling, apoptosis [31]).
However, secretion of type-I IFNs which could have
caused antiviral responses upon virus infection was
not detected in the cell lines tested. This is consistent
with Kirn et al [32] who reported that infection with
oncolytic VACV directly blocks host cell production of
type-I IFN. Certainly, a better understanding of the factors
that affect vaccinia virus and host cell responses would be
useful to improve the biological activity and thus the
potential therapeutic efficacy of oncolytic virotherapy.
Our results also demonstrated that GLV-1h68 efficiently
infiltrates, replicates in and inhibits the growth of human
colorectal tumors in xenograft models. Tumor growth
inhibition was coincident with the peak expression of
Figure 9 Flow cytometry analysis of innate immune cells in untreated and GLV-1h68-treated tumors. A) Representative flow cytometry
plots of macrophage and NK cell populations in uninfected (n=4) and GLV-1h68-infected (n=5) HCT-116 tumors from flow cytometry analysis
experiments at 21 days post treatment are shown. B) Quantification of total F4/80low CXCR4pos macrophages and CD19pos DX5pos NK cells per
gram tumor after normalization by counting beads to quantify the total amount of cells per sample in untreated or GLV-1h68-treated HCT-116
tumors at 21 days post treatment. Average values with standard deviations are plotted. * = P≤0.05, ** = P≤0.005.
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injection, suggesting that the invasion of GLV-1h68 and
its replication in the tumor is the cause of the tumor
growth inhibition. Furthermore, this result was achieved
with only a single injection of GLV-1h68.
Viral infections trigger antiviral responses both in the
infected cells (for example through type I IFN-α/β
signaling) and in the infected organism (through cytokine
and chemokine signaling). These responses recruit and
activate components of the innate immune system to the
site of infection to clear the host from the invading
pathogens and protect it from a systemic infection.
Therefore, the question remains whether the involvement
of the host immune system is beneficial or detrimental to
the virotherapy treatment. Many reports suggest an
important role of the host immune system in eradication
of tumors [33,34], yet antiviral tumor responses can limit
viral replication and spread and therefore limit the effects
of direct oncolysis [35]. As others have reported [12,20,23],
we found that treatment of HCT-116 tumor-bearing mice
with GLV-1h68 up-regulated (from at least 4-fold to230-fold) pro-inflammatory cytokines and chemokines,
like GPC-2, KC/GRO, IFN-γ, IP-10, IL-6, M-CSF-1 ,
MIP-1 beta, MIP-2 and MIP-3, MCP-1, MCP-3, MCP-5,
RANTES and TNF-γ. Interferon gamma is particularly
important for immunity against intracellular pathogens,
including vaccinia virus, and control of tumors and is
produced predominantly by natural killer (NK) cells and
natural killer T (NKT) cells as part of the innate immune
response [36,37]. Additionally, a 66-fold increase was
detected in IP-10 levels, a chemokine attracting T
lymphocytes, monocytes and NK cells to the inflammation
site [38]. Up-regulation of additional chemokines, like KC/
GRO, GPC-2, GM-CSF 1, RANTES and MCP and MIP
family members, also contribute to the recruitment of
components of the innate immune system, exhibiting a
similar role to IP-10. High levels of MCPs leading to
chemotactic recruitment of macrophages, macrophage
activation and subsequent release of MIPs at the site of
inflammation after the treatment with GLV-1h68 should,
and indeed, does promote a strong inflammatory response
at the primary tumor site, as evidenced by the significant
Table 3 GLV-1h68 susceptibility in cell culture and in vivo of CRC cell lines derived from different clinical stages
Cell line Clinical stage GLV-1h68 replication in culture GLV-1h68 cytotoxicity in culture GLV-1h68 treatment in xenograft models
HCT-116 Duke’s type A fast high growth inhibition
HT-29 Duke’s type B fast high non-responder
SW-620 Duke’s type C slow medium growth inhibition
HCT-15 Duke’s type C medium low non-responder
Colo 205 Duke’s type D fast high n.d.
Comparison of five human CRC cell lines derived from patients at different clinical stage of disease regarding virus susceptibility (replication and cytotoxicity) in
cell culture and treatment efficacy in mouse xenograft models of five human CRC cell lines at different clinical stages. n.d. = not determined.
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tumors of virus-treated animals.
It has been suggested that the tumor microenvironment
presents a niche that promotes aberrant proliferation of
malignant cells while offering protection from the host
immune system. Cancers possess a broad repetoire of
means to evade the host defense, including mimicking self,
down-regulation of MHC molecules and interference
with antigen presentation, production of factors that are
lethal to or paralyzing T cells and lastly recruitment of
so-called regulatory immune cells (tumor-infiltrating
leukocytes, myeloid-derived suppressor cells (MDSCs)
and regulatory T cells) that control effector immune cell
functions and ultimately promote the evasion of immune
surveillance [39].
We believe that infection of the tumor with GLV-1h68
disturbs this “immune-protected” microenvironment.
Viral replication and direct oncolysis in the tumor leads to
the observed increase in expression of chemoattractants
and activators of maturation for components of the innate
immune system (macrophages, NK cells, dendritic
cells, neutrophils), thus creating a pro-inflammatory
environment. Also, ongoing necrosis by viral oncolysis
and the recruited components of innate immunity may
facilitate influx of de novo immune cells into the
previously immune-protected tumor microenvironment.
Mature dendritic cells and macrophages might act as
mediators that cross-talk with the naïve T cells to elicit
an adaptive immune response against the tumor cells
through activation by MHC class II tumor antigen presen-
tation. Indeed, our results and observations demonstrate
that, in contrast to untreated tumors, vaccinia virus infec-
tion triggers pro-inflammatory cytokine signaling in colo-
rectal cancer tumors, followed by recruitment of cells of
the innate immune system to the inflamed tumor site.
These events could contribute to or augment the inhib-
ition of growth and regression of the tumor, as proposed
by Worschech et al [12].
Interestingly, we found SGOT levels in GLV-1h68-treated
animals to be reduced compared to untreated animals.
It has been shown that SGOT levels in the blood may
be an indicator of liver or heart damage, or cancer. The
elevated levels of SGOT in the untreated animals maysimply reflect the higher tumor burden in these ani-
mals. Alternatively, the high levels of SGOT in the un-
treated animals could indicate the presence of liver
metastasis, although no physical evidence of tumors
were observed grossly.
For overall treatment efficacy, especially in late stage
colorectal cancer, it is important that the oncolytic
vaccinia virus GLV-1h68 also targets, invades and de-
stroys distant metastases in addition to the primary
tumor. In this study we demonstrated that GLV-1h68
infected and killed colorectal cancer cells derived both
from primary tumors (HCT-116, Duke’s type A, HT-29,
Duke’s type B and HCT-15, Duke’s type C) and metastatic
sites (SW-620, Duke’s type C and Colo 205, Duke’s type
D) in culture and in vivo (Table 3).
Increasingly, reports have implicated colorectal cancer
stem cells and their chemoresistant properties especially in
the recurrence of tumors. Recently, Wang et al. reported
that oncolytic vaccinia virus GLV-1h68 showed enhanced
replication in human breast cancer stem-like cells in
comparison to breast cancer cells [40]. These observations
imply that conventional treatment approaches involving
surgery and chemotherapy could significantly benefit in
combination with treatment with oncolytic virus
GLV-1h68 to target and eliminate remaining colorectal
cancer (−initiating) cells and to reduce recurrence rates
even in early stage detected CRCs and improve overall
prognosis of the disease.
That GLV-1h68 is administered systemically and
efficiently infects and kills tumors and metastases
in vivo [20] presents a powerful tool for the non-
invasive treatment of colorectal cancers, even in later
stage progression of the disease when conventional
treatments are ineffective.
Conclusion
We have shown for the first time that the oncolytic
replication-competent vaccinia virus strain GLV-1h68 can
efficiently infect, replicate in, and lyse different colorectal
cancer lines in culture, independent from their original
stage of prognosis when obtained from the patient. Fur-
thermore, we showed that GLV-1h68 specifically targets
and exclusively replicates in HCT-116 (Duke’s type A)
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grafts in mice. While surgical excision of primary colo-
rectal tumors in combination with chemotherapy allows
for a good survival prognosis but a recurrence rate of
40-60% of the disease, late stage colorectal cancer with
metastasis to the lymph nodes or distant body organs is
still fatal and treatment options palliative. The mild side
effects of vaccinia virus administration and its ability to
target and destroy colorectal cancer cells irrespective of
the stage of disease makes oncolytic virotherapy, possibly
in combination with conventional therapy, particularly
promising for the future treatment and control of colorec-
tal cancer.
Additional files
Additional file 1: Fluorescence microscopy of virus-mediated Ruc-GFP
expression in HCT-116. CRC cells were infected with at MOI of 0.1 and
monitored for 72 h. (BF) shows bright field microscopic images of the
morphology of virus-infected cells. (GFP) expression in infected cells was
visualized by direct fluorescence; propidium iodide (PI) was used as a
marker for dead cells. Colocalization of (GFP) and (PI) signal is shown in the
(merged) images. All pictures were taken at 40x magnification.
Additional file 2: Flow cytometry analysis of infection of various
colorectal cancer cell lines. Cells were infected at MOIs of 0.1 and 1.0.
Data represents the average distribution of uninfected/infected [GFP
neg/pos] and viable/dead [PI neg/pos] cells in triplicate over the course
of 72 hours post-infection.
Additional file 3: Changes in net body weight and overall survival of
untreated and treated animals. A) Net body weight (g) was calculated
using the following formula: body weight (g) – (tumor volume/1000 mm3).
B) Overall survival is plotted as a Kaplan-Meier survival diagram; n=10 for
GLV-1h68-treated group, n=5 for PBS-treated group.
Additional file 4: Effects of a single administration of GLV-1h68 on
tumor development of SW-620 tumor-bearing mice. SW-620 cells were
implanted subcutaneously in the right hind leg of athymic nude mice and
treated by injection GLV-1h68 or PBS. Virus treatment was tested versus PBS
treatment. Average tumor volume (ATV) of [n=10 for GLV-1h68-treated, n=5
for PBS treated controls] mice is plotted and one-way analysis of variance
(ANOVA) was used to compare the data. P ≤ 0.05 was considered
statistically significant; * = P ≤ 0.05.
Abbreviations
ANOVA: Analysis of variation; ATV: Average tumor volume; BF: Bright field;
CPE: Cytopathic effect; CRC: Colorectal cancer; dpi: Days post injection;
FBS: Fetal bovine serum; FGF: Fibroblast growth factor; GFP: Green
fluorescent protein; GM-CSF: Granulocyte-macrophage colony-stimulating
factor; GCP: Granulocyte chemotactic protein; hpi: Hours post infection;
IFN-α/β/γ: Interferon alpha/beta/gamma; IL: Interleukin; IP-10: Interferon
gamma-induced protein 10; i.v.: Intravenous; KC/GRO: Growth-regulated
alpha protein; LSD: Least significant difference; MAP: Multi analyte profile;
M-CSF: Macrophage colony-stimulating factor; MIP: Macrophage
inflammatory protein; MCP: Monocyte chemotactic protein; MDSCs: Myeloid-
derived suppressor; MOI: Multiplicity of infection; NK: Natural killer;
pfu: Plaque forming unit; PI: Propidium iodide; RANTES: Regulated and
normal T cell expressed and secreted; RBC: Red blood cell Ruc: Renilla
luciferase; rVACV: Recombinant vaccinia virus; s.c.: Subcutaneous;
SGOT: Serum glutamic oxaloacetic transaminase; TLR: Toll-like receptor;
TNF-α: Tumor necrosis factor alpha.
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